Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd (APLLTD) last reported results for the quarter ended Jun 2026, with sales of ₹2,150 crore and net profit of ₹172 crore. The stock last traded at ₹833, a market capitalisation of ₹16,374 crore, on a P/E of 21.9. Over the past 52 weeks the stock has ranged between ₹635 and ₹998. Figures are as of 6 Oct 2026 and are not real time.
Alembic Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹833
- Market cap
- ₹16,374 cr
- Stock P/E
- 21.9
- Book value
- ₹289
- ROE
- 13.4%
- ROCE
- 12.6%
- Dividend yield
- 1.44%
- 52w high / low
- 998/635
Metrics as of 6 Oct 2026. Not real time.
Track Alembic Pharmaceuticals Ltd
Cruxal reads every Alembic Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Alembic Pharmaceuticals Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- 6%
- 3 Years
- 9%
- TTM
- 14%
- 10 Years
- 0%
- 5 Years
- -9%
- 3 Years
- 28%
- TTM
- 26%
- 10 Years
- 2%
- 5 Years
- 1%
- 3 Years
- 2%
- 1 Year
- -8%
- 10 Years
- 16%
- 5 Years
- 11%
- 3 Years
- 13%
- Last Year
- 13%
Alembic Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,150 cr, up 25.7% from ₹1,711 cr a year earlier. Net profit was ₹172 cr, up 11.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 |
| Expenses | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 | 1,585 | 1,620 | 1,818 |
| Operating profit | 239 | 260 | 271 | 281 | 316 | 292 | 228 | 332 |
| OPM % | 15% | 15% | 15% | 16% | 17% | 16% | 12% | 15% |
| Other income | 30 | 10 | 14 | 6 | 8 | -27 | 2 | 15 |
| Interest | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 |
| Depreciation | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 |
| Profit before tax | 180 | 178 | 192 | 190 | 224 | 162 | 119 | 222 |
| Tax % | 15% | 23% | 18% | 19% | 18% | 18% | -70% | 22% |
| Net profit | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 |
| EPS (₹) | 7.80 | 7.04 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 | 8.80 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Alembic Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 | 7,784 |
| Operating profit | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 932 | 1,008 | 1,121 | 1,167 |
| OPM % | 20% | 21% | 22% | 27% | 27% | 16% | 12% | 15% | 15% | 15% | 15% |
| Net profit | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 616 | 582 | 671 | 690 |
| EPS (₹) | 21.39 | 21.89 | 31.00 | 43.97 | 58.33 | 26.50 | 17.40 | 31.33 | 29.68 | 34.33 | 35.27 |
TTM is the trailing twelve months to the most recent quarter.
Alembic Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,779 | 5,152 | 5,636 |
| Borrowings | 89 | 708 | 1,128 | 1,747 | 584 | 717 | 722 | 513 | 1,258 | 1,430 |
| Other liabilities | 698 | 1,013 | 931 | 1,022 | 1,058 | 1,167 | 1,090 | 1,114 | 1,325 | 1,658 |
| Total liabilities | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,763 |
| Fixed assets | 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,547 | 2,524 | 3,081 |
| CWIP | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 524 | 837 | 683 |
| Investments | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 | 127 | 141 |
| Other assets | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,281 | 4,285 | 4,858 |
| Total assets | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 | 7,773 | 8,763 |
As reported by the company. Total assets equal total liabilities by construction.
Alembic Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 | 803 | 88 | 783 |
| Cash from investing | -486 | -884 | -756 | -731 | -840 | -372 | -448 | -321 | -568 | -506 |
| Cash from financing | -129 | 503 | 59 | 155 | -597 | -217 | -262 | -438 | 444 | -164 |
| Net cash flow | -286 | -69 | 115 | -127 | 26 | -37 | 14 | 45 | -37 | 113 |
| Free cash flow | 348 | -495 | 49 | -285 | 804 | 128 | 282 | 487 | -466 | 290 |
| CFO / operating profit | 73% | 70% | 112% | 56% | 115% | 77% | 115% | 88% | 16% | 79% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Alembic Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 29% | 22% | 23% | 24% | 26% | 11% | 7% | 13% | 13% | 13% |
| Debtor days | 40 | 61 | 45 | 69 | 24 | 56 | 68 | 60 | 77 | 73 |
| Inventory days | 269 | 302 | 356 | 417 | 431 | 406 | 315 | 350 | 466 | 462 |
| Days payable | 213 | 313 | 237 | 220 | 194 | 178 | 145 | 157 | 179 | 154 |
| Cash conversion cycle | 96 | 51 | 164 | 266 | 261 | 283 | 237 | 253 | 363 | 381 |
| Working capital days | 61 | 69 | 24 | 50 | 73 | 74 | 77 | 88 | 87 | 87 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Alembic Pharmaceuticals Ltd shareholding pattern
Promoters held 69.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 4.17% and DIIs 15.93%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.61% | 69.61% | 69.67% | 69.68% | 69.74% | 69.74% | 69.74% | 69.87% |
| FIIs | 3.94% | 4.17% | 3.94% | 3.96% | 4.04% | 4.23% | 4.26% | 4.17% |
| DIIs | 16.05% | 16.05% | 16.43% | 16.46% | 16.30% | 16.17% | 16.17% | 15.93% |
| Public | 10.38% | 10.17% | 9.96% | 9.91% | 9.92% | 9.84% | 9.83% | 10.00% |
| No. of shareholders | 91,429 | 93,944 | 91,336 | 89,013 | 89,969 | 87,000 | 86,432 | 86,796 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Alembic Pharmaceuticals Ltd corporate filings
- Alembic Pharmaceuticals publishes newspaper notice, no financial or operational updates includedCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals Ltd released a newspaper publication on 8th October 2026, with no…
Read the full analysis - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find enclosed Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Read the full analysis - DSP Mutual Fund reduces stake in Alembic Pharmaceuticals to 2.97%Insider Trading / SASTlow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has received a disclosure under SEBI (SAST) Regulations…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find enclosed Intimation of Trading Window Closure.
Read the full analysis - Alembic Pharmaceuticals Ltd schedules one-to-one investor meetingCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has issued an intimation regarding a one-to-one investor meeting…
Read the full analysis - Alembic Pharmaceuticals provides update on USFDA inspection of Vadodara bioequivalence facilityCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has issued an update regarding the USFDA inspection conducted at…
Read the full analysis - Alembic Pharmaceuticals completes unannounced USFDA inspection of Vadodara bioequivalence facilityCompany Updatemedium impact
Cruxal's analysis: Alembic Pharmaceuticals has successfully completed an unannounced onsite inspection by…
Read the full analysis - Alembic Pharmaceuticals incorporates new wholly owned subsidiaryCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has announced the incorporation of a new wholly owned subsidiary…
Read the full analysis - Alembic Pharmaceuticals Ltd announces analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has filed an intimation regarding an upcoming analyst/investor…
Read the full analysis - Alembic Pharmaceuticals Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has issued an intimation regarding an upcoming analyst/investor…
Read the full analysis - Alembic Pharmaceuticals Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has fulfilled its regulatory obligation under Regulation 30 of…
Read the full analysis - Alembic Pharmaceuticals Limited appoints Mr. Chirag Shukla as Company Secretary and Compliance OfficerCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has announced the appointment of Mr. Chirag Shukla as the…
Read the full analysis - Alembic Pharmaceuticals Ltd: Newspaper publication of financial results noticeCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has published a notice in newspapers regarding the disclosure of…
Read the full analysis - Alembic Pharmaceuticals Limited announces resignation of Company Secretary and Compliance OfficerCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has formally notified the stock exchanges regarding the…
Read the full analysis - Alembic Pharmaceuticals Q1 FY27 Earnings Call: Strong 26% Revenue Growth and Upward Guidance RevisionCompany Updatehigh impact
Cruxal's analysis: Alembic Pharmaceuticals reported a strong Q1 FY27 with consolidated revenue growing 26%…
Read the full analysis - Alembic Pharmaceuticals Limited Announces Successful Conclusion of 16th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has successfully concluded its 16th Annual General…
Read the full analysis - Alembic Pharmaceuticals Limited concludes 16th Annual General Meeting; key resolutions include dividend declaration and director appointmentsAGM/EGMlow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has successfully concluded its 16th Annual General…
Read the full analysis - Alembic Pharmaceuticals Ltd releases mandatory newspaper advertisement for regulatory complianceCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has published a routine newspaper advertisement in compliance…
Read the full analysis - Alembic Pharmaceuticals releases audio recording of investor callCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has filed the audio recording of its recent investor/analyst…
Read the full analysis - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Company Updatemedium impact
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.